Chugai Pharmaceutical stock at EUR 33.98 with volume 9.4 percent above average

Published on 10/09/2026 at 15:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 17.8 percent year over year to JPY 341.58 billion. Chugai Pharmaceutical stock costs EUR 33.98 after EUR 34.33 on October 9, 2026.

Key points in brief

Chugai Pharmaceutical stock was EUR 33.98 at Lang & Schwarz on October 9, 2026, with a 1.02 percent decline versus the prior close.
Trading volume reached 3,116,800 shares, 9.4 percent above the average of 2,850,158 shares.
Second-quarter revenue rose 17.8 percent year over year to JPY 341.58 billion, while net income reached JPY 116.33 billion.
Chugai's next fiscal 2026 third-quarter results are scheduled for October 27, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (JP3519400000) was trading at EUR 33.98 at Lang & Schwarz on October 9, 2026 at 3:11 p.m. CEST. The price was down 1.02 percent versus the Lang & Schwarz prior close of EUR 34.33, while volume reached 3,116,800 shares, 9.4 percent above the average of 2,850,158 shares.

Price sits near yearly low

The bid was EUR 33.65 and the ask EUR 34.31 at the same Lang & Schwarz timestamp. On the Tokyo Stock Exchange, Chugai last traded at JPY 6,019 on October 9, 2026 at 3:30 p.m. JST, against a 52-week range of JPY 5,974 to JPY 10,700. The Tokyo price stood 43.7 percent below its 52-week high.

Second-quarter growth remains visible

Markets Insider reported that Chugai's second-quarter revenue rose 17.8 percent year over year to JPY 341.58 billion, while net income increased to JPY 116.33 billion from JPY 97.16 billion in the comparable period. The figures place the current market move beside a clear operating comparison rather than a single-session price signal.

Chugai's valuation also differs from its large Japanese peers. Its price-to-earnings ratio was 21.01, compared with 52.09 for Takeda Pharmaceutical and 19.87 for Daiichi Sankyo, using October 9, 2026 market data.

Comparison with peers

Chugai Pharmaceutical: minus 1.02 percent, P/E 21.01, market capitalization JPY 9.9 trillion
Takeda Pharmaceutical (Tokyo Stock Exchange, JPY): plus 0.46 percent, P/E 52.09, market capitalization JPY 9.3 trillion
Daiichi Sankyo (Tokyo Stock Exchange, JPY): minus 1.15 percent, P/E 19.87, market capitalization JPY 4.8 trillion

Next results date is October 27

Chugai's investor-relations calendar lists fiscal 2026 third-quarter results for October 27, 2026, covering the January to September period, with the financial results scheduled for 5:00 p.m. JST. The date is supplied by Chugai Pharmaceutical.

Chugai Pharmaceutical's healthcare business is classified as drug manufacturing, and its market capitalization was JPY 9.9 trillion on October 9, 2026. The stock's 21.01 price-to-earnings ratio sits between Daiichi Sankyo's 19.87 and Takeda Pharmaceutical's 52.09.

Price and trading context

Chugai was trading at EUR 33.98 at Lang & Schwarz on October 9, 2026 at 3:11 p.m. CEST, down 1.02 percent versus the prior close of EUR 34.33. The comparison remains anchored to the German euro quote, while the Tokyo listing provides the home-market context.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.